Gynaec Cancer Fertility Preservation Myths — Dr. Nishtha Tripathi Patel is an ESGO-certified gynaecological oncosurgeon offering expert gynaec cancer fertility preservation myths care at Sterling Hospitals, KD Hospital, and Welcare Speciality Hospital in Ahmedabad.
A cancer diagnosis in young women raises immediate fertility concerns. Below are five myths that delay or deny patients fertility-preserving treatment when it is actually feasible.
On this page
- 1. Myth: A cancer diagnosis means no chance of biological children
- 2. Myth: Fertility preservation increases the risk of recurrence
- 3. Myth: Only single, young women qualify
- 4. Myth: Fertility-preserving surgery is the same as IVF preservation
- 5. Myth: You have time to decide after starting treatment
Gynaec cancer fertility preservation myths — 1. Myth: A cancer diagnosis means no chance of biological children
For selected early-stage cervical, ovarian, and endometrial cancers, fertility-preserving options exist that do not compromise oncological outcomes. The opportunity is time-limited; it must be discussed before surgery, not after.
2. Myth: Fertility preservation increases the risk of recurrence
In carefully selected patients meeting strict eligibility criteria, fertility-preserving surgery (radical trachelectomy, unilateral salpingo-oophorectomy, conservative hormonal management) has been shown to have similar recurrence rates to standard surgery. Patient selection is the key.
3. Myth: Only single, young women qualify
Fertility preservation is discussed for any woman of reproductive age (typically up to 40-42) who has not completed her family — married or single. Reproductive intent matters more than marital status.
4. Myth: Fertility-preserving surgery is the same as IVF preservation
These are different. Surgical preservation (e.g. radical trachelectomy) keeps the reproductive organ intact for natural or assisted conception later. IVF preservation (egg or embryo freezing before chemotherapy) is a separate, complementary option.
5. Myth: You have time to decide after starting treatment
Fertility-preserving options must be considered BEFORE definitive treatment begins. Once a radical hysterectomy or extensive chemotherapy is done, options narrow significantly. Plan early — even a few days of delayed referral matters less than weeks.
What to do next
If you have been diagnosed with a gynaecological cancer and want to preserve fertility, request an urgent consultation with Dr. Nishtha Tripathi Patel. WhatsApp +91 76988 00333.
Related
External reference: ESGO Fertility-Sparing Treatment Guidelines.
FAQs
Myth: A cancer diagnosis means no chance of biological children
For selected early-stage cervical, ovarian, and endometrial cancers, fertility-preserving options exist that do not compromise oncological outcomes. The opportunity is time-limited; it must be discussed before surgery, not after.
Myth: Fertility preservation increases the risk of recurrence
In carefully selected patients meeting strict eligibility criteria, fertility-preserving surgery (radical trachelectomy, unilateral salpingo-oophorectomy, conservative hormonal management) has been shown to have similar recurrence rates to standard surgery. Patient selection is the key.
Myth: Only single, young women qualify
Fertility preservation is discussed for any woman of reproductive age (typically up to 40-42) who has not completed her family — married or single. Reproductive intent matters more than marital status.
Myth: Fertility-preserving surgery is the same as IVF preservation
These are different. Surgical preservation (e.g. radical trachelectomy) keeps the reproductive organ intact for natural or assisted conception later. IVF preservation (egg or embryo freezing before chemotherapy) is a separate, complementary option.
Myth: You have time to decide after starting treatment
Fertility-preserving options must be considered BEFORE definitive treatment begins. Once a radical hysterectomy or extensive chemotherapy is done, options narrow significantly. Plan early — even a few days of delayed referral matters less than weeks.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified.